克雷森特生物制药 CBIO
$13.54 +$0.60 (+4.64%)
休市 · Nov 6, 8:10 pm ET · 最新盘后价 $13.54 0.00%
开盘$12.84
昨收$12.94
当日区间$12.75 – $13.91
成交量137.8K
市值$502.93M
市盈率（TTM）–
股息率–
CBIO 相关新闻
匹配 Crescent Biopharma 或代码 CBIO 的头条新闻，按最新排序。
- H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Hold Rating
- Piper Sandler Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35
- Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $30
- Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Sionna Therapeutics, Inc. (SION) and Crescent Biopharma (CBIO)
- Wedbush Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $27
- H.C. Wainwright Downgrades Crescent Biopharma(CBIO.US) to Hold Rating 负面
- H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22
- Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $30 负面
- A Quick Look at Today's Ratings for Crescent Biopharma(CBIO.US), With a Forecast Between $27 to $35
- H.C. Wainwright Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Cuts Target Price to $22 负面
- LifeSci Capital Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $22
- TD Cowen Maintains Crescent Biopharma(CBIO.US) With Buy Rating
- Guggenheim Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $35
- Stifel Maintains Crescent Biopharma(CBIO.US) With Buy Rating, Maintains Target Price $28
- H.C. Wainwright Upgrades Crescent Biopharma(CBIO.US) to Buy Rating, Announces Target Price $36 正面
暂无评论——快来第一个聊聊 CBIO。
登录后参与讨论。